

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ZYDUS LIFESCIENCES LIMITED, ZYDUS LIFESCIENCES
GLOBAL FZE, and ZYDUS PHARMACEUTICALS (USA) INC.,
Petitioner,

v.

BIOMARIN PHARMACEUTICAL INC.,
Patent Owner.

Case PGR2026-00055
Patent No. 12,233,106 B2

PATENT OWNER'S CURRENT LIST OF EXHIBITS

LIST OF EXHIBITS

Exhibit No.	Description	Previously Submitted
2001	Press Release: FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism, FDA (Nov. 19, 2021), https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism .	X
2002	Press Release: U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia, BioMarin (Oct. 20, 2023), https://www.biomin.com/news/press-releases/u-s-food-and-drug-administration-approves-biominins-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia/ .	X
2003	<i>BioMarin Pharmaceutical Inc. v. Zydus Lifesciences Ltd.</i> , 1:26-cv-1005, D.I. 1 (D.N.J.)	X
2004	Correspondence with Honorable Board	

Respectfully submitted,

Dated: September 18, 2026

By: /Naveen Modi/
Naveen Modi (Reg. No. 46,224)
Counsel for Patent Owner

CERTIFICATE OF SERVICE

I hereby certify that on September 18, 2026, I caused a true and correct copy of the foregoing Patent Owner's Current List of Exhibits to be served via email on Petitioner at the following addresses:

Roger H. Lee (roger.lee@bipc.com)
Todd R. Walters (todd.walters@bipc.com)
David M. Knapp (david.knapp@bipc.com)
Jacob C. Britz (jacob.britz@bipc.com)

Respectfully submitted,

Dated: September 18, 2026

By: /Naveen Modi/
Naveen Modi (Reg. No. 46,224)
Counsel for Patent Owner